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Triple-negative breast cancer (TNBC) is associated with high grade, metastatic phenotype,
younger patient age, and poor prognosis. The discovery of an effective anti-TNBC agent has
been a challenge in oncology. In this study, fifty-eight ester derivatives (DETDs) with a
novel sesquiterpene dilactone skeleton were organically synthesized from a bioactive nat-
ural product deoxyelephantopin (DET). Among them, DETD-35 showed potent antiprolifer-
ative activities against a panel of breast cancer cell lines including TNBC cell line MDA-MB-
231, without inhibiting normal mammary cells M10. DETD-35 exhibited a better effect than
parental DET on inhibiting migration, invasion, and motility of MDA-MB-231 cells in a
concentration-dependent manner. Comparative study of DETD-35, DET and chemothera-
peutic drug paclitaxel (PTX) showed that PTX mainly caused a typical time-dependent
G2/M cell-cycle arrest, while DETD-35 or DET treatment induced cell apoptosis. In vivoylate; DET, deoxyelephantopin; DETD, deoxyelephantopin derivative; DMAP, dimethylami-
)-3-ethylcarbodiimide hydrochloride; ER, estrogen receptor; HER2, human epidermal growth
)-2,5-diphenyl tetrazolium bromide; PTX, paclitaxel; PR, progesterone receptor; SAR, struc-
tive breast cancer.
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MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 9 2 1e9 3 7922Lung metastasisPaclitaxelefficacy of DETD-35 was evaluated using a lung metastatic MDA-MB-231 xenograft mouse
model. DETD-35 significantly suppressed metastatic pulmonary foci information along
with the expression level of VEGF and COX-2 in SCID mice. DETD-35 also showed a syner-
gistic antitumor effect with PTX in vitro and in vivo. This study suggests that the novel com-
pound DETD-35 may have a potential to be further developed into a therapeutic or
adjuvant agent for chemotherapy against metastatic TNBC.
ª 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction activities (Farha et al., 2014; Geetha et al., 2012; Kabeer et al.,Breast cancer is a commonly diagnosed cancer amongwomen.
Although multiple breast cancer therapy protocols including
hormone modulators and antibody preparations have been
developed, the mortality rate from breast cancer has not
improved over the past decade (Howlader et al., 2012). Eighty
percent of breast cancers are invasive and recurrence is prob-
lematic. The search for effective therapies for breast cancers
is complicatedby its heterogeneouspathologies andmolecular
profiles. It is known that many breast cancers are associated
with overexpression of either one or multiple hormone recep-
tors such as estrogen receptors (ER), progesterone receptors
(PR), andhumanepidermal growth receptor 2 (HER2).Hormone
therapies and/or molecular targeted therapies are applied as
an effective treatment for such types of breast cancer. Howev-
er, difficulties are associated with the treatment of breast can-
cerwithheterogeneous triple-negative type lacking ER, PR, and
HER2 expression,which accounts for 15e20%of breast cancers
and usually has poor prognosis, and the discovery of an effec-
tive anti-breast cancer agent that targets triple-negative breast
cancer (TNBC) has been a challenge in oncology.
Elephantopus scaber, a plant from the Asteraceae family, is
widely distributed in Eastern and Southeast Asia, Africa,
Australia, as well as the Indian subcontinent. It has been
widely used as a traditional medicine for the treatment of
various diseases and symptoms, such as hepatitis, fever,
cough, asthma, arthritis, leukemia, and rheumatism (Kabiru
and Por, 2013). Recent research has also revealed its varied
pharmacological activities, such as antimicrobial, antidiar-
rheal, antidiabetic, analgesic, anti-inflammatory, as well as
antitumor activities (Hiradeve and Rangari, 2014). Deoxyele-
phantopin (DET, 1), a sesquiterpene dilactone, is a major
component of E. scaber, and was first isolated in 1970 from a
different Elephantopus species (Govindac et al., 1970;
Kurokawa et al., 1970). Among the diverse sesquiterpene lac-
tones, DET contains a germacranolide skeleton, a ten-
membered ring with a trans-fused a-methylene-g-lactone,
combined together with an additional g-lactone and methac-
rylate at C-8. It is believed that a,b-unsaturated ketones
including an a-methylene-g-lactone group on the skeleton
are associated with a variety of biological effects. This often
acts as a Michael acceptor for nucleophiles such as the thiol
group commonly found in the target protein and enzyme
(Kupchan et al., 1971; Lee et al., 1971; Picman, 1986). Biological
activities, such as hepatoprotective (Huang et al., 2013), anti-
trypanosomal (Zahari et al., 2014), and anti-cancer cell2013; Lee et al., 2010; Lee and Shyur, 2012; Su et al., 2011;
Zou et al., 2008) have been reported for plant sesquiterpene
lactones. Our recent studies have also revealed that DET pos-
sesses potent activity against TS/A (ERþ) mammary tumor
growth and metastasis in syngeneic mice through inhibiting
m-calpain activity and induction of centrosomal ubiquiti-
nated protein aggregates, protein carbonylation and ER
stress-mediated apoptosis that led to significant attenuation
of cancer cell motility and metastasis (Huang et al., 2010; Lee
et al., 2010; Lee and Shyur, 2012). In spite of the already
observed anti-tumor activities of DET, whether DET or its de-
rivatives is effective for inhibiting TNBC remains unknown.
In this study,wereport thedesignandsynthesisofa seriesof
DETderivatives (DETDs), and the structure-activity relationship
(SAR) of theparental DET andDETDswere addressed. Themost
potent DETD derivate, namely DETD-35, as well as DET, along
with a reference chemotherapeutic drug paclitaxel against
TNBCeffects in vitroand in vivoand theunderlyingmechanisms
were comparatively investigated. This study provides a novel
DETD that may constitute a new class of anti-TNBC agent.2. Material and methods
2.1. Chemicals and reagent
All chemicals and solventswere used as purchased. Allmelting
points were measured on a Fisher-Johns melting point appa-
ratus and reportedwithout correction. 1H and 13C-NMR spectra
were recorded on a Varian Gemini 2000 (300 MHz) or Varian
Inova (400 MHz) NMR spectrometer with TMS as the internal
standard. All chemical shifts are reported in ppm. NMR spectra
were referenced to the residual solvent peak, chemical shifts
d in ppm, apparent scalar coupling constants J inHz.Mass spec-
troscopic data were obtained on a Shimadzu LCMS-IT-TOF in-
strument and JEOL JMS-700 MStation for FAB. Analytical thin-
layer chromatography was carried out on Merck precoated
aluminum silica gel sheets (Kieselgel 60 F-254). CombiFlash
(IscoCompanionsystems)wereused forflashchromatography.
All target compoundswere characterized and determined to be
at least >95% pure by 1H-NMR, HRMS, and analytical HPLC.2.2. Deoxyelephantol 2
Aqueous 1 N NaOH (25.0 mL) at 0 C was added to a solution of
DET (1, 1.023 g, 2.97 mmol) in dioxane (25.0 mL). The mixture
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The mixture was acidified with aqueous 2 N HCl and stirred
for 30 min, and then extracted twice with AcOEt then 5%
MeOH/AcOEt. The combined organic layers were washed
with brine, dried over Na2SO4, and concentrated in vacuo.
The residue was purified with column chromatography on
SiO2 to obtain the novel dilactone alcohol 2 (0.744 g,
2.70 mmol, 91%). 1H-NMR (400 MHz, 2% CD3OD/CDCl3) 6.99
(1H, s), 6.41 (1H, dd, J ¼ 3.1 and 1.2 Hz), 6.32 (1H, dd, J ¼ 2.7
and 1.2 Hz), 5.47e5.43 (1H, m), 4.56 (1H, br d, J ¼ 10.0 Hz),
4.27 (1H, t, J ¼ 9.7 Hz), 4.10 (1H, ddd, J ¼ 10.7, 6.4 and 1.6 Hz),
3.19 (1H, ddd, J ¼ 13.1, 3.8 and 1.6 Hz), 2.89e2.82 (1H, m), 2.77
(1H, dd, J ¼ 13.5 and 4.7 Hz), 2.67 (1H, dd, J ¼ 13.1 and
10.7 Hz), 2.57 (1H, br d, J ¼ 13.5 Hz), 1.71 (3H, d,
J ¼ 1.4 Hz).13C-NMR (400 MHz, 2% CD3OD/CDCl3) 172.9, 169.4,
155.2, 140.3, 136.3, 127.2, 126.2, 125.7, 80.9, 78.5, 67.7, 50.9,
40.5, 31.8, 19.0. [a]22D þ42.5 (c 0.1, MeOH), HRMS-FAB: m/z
(Mþ þ Na) calcd for C15H16O5 299.0890, found 299.0883. Crystal
data is shown in the Supporting information.
2.3. Preparation of DET derivatives from 2
General procedure for Method A: To a solution of 2 (25 mg,
0.09 mmol) in methylene chloride (2.0 mL), 3-methoxycin
namic acid (80 mg, 0.45 mmol), 1-(3-dimethylaminopropyl)-
3-ethylcarbodiimide hydrochloride (EDCI, 92 mg, 0.48 mmol)
and dimethylaminopyridine (DMAP, 12 mg, 0.1 mmol) were
added. The mixture was stirred at room temperature over-
night. Standard work-up was performed to obtain DETD-39
(33, 28 mg, 71%).
General procedure for Method B: 4-Bromobenzoyl chloride
(55 mg, 0.25 mmol) and triethylamine (0.05 mL) at 0 C were
added to a solution of 2 (29 mg, 0.11 mmol) in methylene chlo-
ride (2.0 mL). The mixture was stirred at room temperature
overnight. Standard work-up was performed to obtain 46
(39 mg, 81%).
2.4. Methacrylate 7 (Method A)
1H-NMR (400 MHz, CDCl3): 6.93 (1H, s), 6.40 (1H, d, J ¼ 2.7 Hz),
6.10 (1H, d, J ¼ 9.6 Hz), 5.94 (1H, d, J ¼ 2.1 Hz), 5.65 (1H, s),
5.45 (1H, br s), 5.39 (1H, t, J ¼ 10.0 Hz), 4.57 (1H, d,
J ¼ 10.0 Hz), 4.23 (1H, dd, J ¼ 10.1 and 6.5 Hz), 3.28 (1H, d,
J ¼ 13.1 Hz), 3.15 (1H, ddd, J ¼ 10.0, 6.5 and 3.3 Hz), 2.79 (1H,
dd, J ¼ 13.6 and 4.9 Hz), 2.68 (1H, dd, J ¼ 13.1 and 10.8 Hz),
2.54 (1H, d, J ¼ 13.6 Hz), 1.95 (3H, s), 1.87 (3H, s). HRMS-FAB:
m/z (Mþ þ Na) calcd for C19H20O6 367.1158, found 367.1171.
2.5. Cinnamate 28 (DETD-6) (Method A)
1H-NMR (400 MHz, CDCl3): 7.71 (1H, d, J ¼ 16.0 Hz), 7.55e7.50
(2H, m), 7.44e7.38 (3H, m), 6.94 (1H, s), 6.41 (1H, d, J ¼ 9.6 Hz),
6.40 (1H, d, J ¼ 16.0 Hz), 6.00 (1H, d, J ¼ 2.5 Hz), 5.50e5.44 (2H,
m), 4.51 (1H, d, J ¼ 10.0 Hz), 4.25 (1H, ddd, J ¼ 10.5, 6.5 and
1.6 Hz), 3.33e3.26 (1H, m), 3.19e3.11 (1H, m), 2.80 (1H, dd,
J ¼ 13.5 and 4.9 Hz), 2.69 (1H, dd, J ¼ 13.1 and 10.7 Hz), 2.55
(1H, d, J ¼ 13.5 Hz), 1.89 (3H, d, J ¼ 1.4 Hz). HRMS-ESI: m/z
(Mþ þ H) calcd for C24H22O6 407.1489, found 407.1475.2.6. (E)-3-Methoxycinnamate 33 (DETD-39) (Method A)
1H-NMR (400 MHz, CDCl3): 7.66 (1H, d, J ¼ 15.9 Hz), 7.32 (1H, t,
J ¼ 8.0 Hz), 7.11 (1H, d, J ¼ 7.8 Hz), 7.05e7.01 (1H, m), 6.96 (1H,
dd, J ¼ 8.0 and 2.5 Hz), 6.93 (1H, br s), 6.41 (1H, d, J ¼ 2.9 Hz),
6.38 (1H, d, J ¼ 15.9 Hz), 6.00 (1H, d, J ¼ 2.9 Hz), 5.45 (1H, t,
J ¼ 10.1 Hz), 4.50 (1H, d, J ¼ 10.1 Hz), 4.25 (1H, ddd, J ¼ 10.5,
6.6 and 1.6 Hz), 3.84 (3H, s), 3.29 (1H, br d, J ¼ 13.0 Hz),
3.19e3.11 (1H, m), 2.80 (1H, dd, J ¼ 13.3 and 4.9 Hz), 2.69 (1H,
dd, J ¼ 13.3 and 10.5 Hz), 2.54 (1H, d, J ¼ 13.3 Hz), 1.89 (3H, d,
J ¼ 1.2 Hz). HRMS-FAB: m/z (Mþ þ Na) calcd for C25H24O7
459.1420, found 459.1423.2.7. 4-Methoxybenzoate 44 (DETD-32) (Method B)
1H-NMR (400MHz, CDCl3): 7.96 (2H, d, J¼ 8.0 Hz), 6.97e6.92 (3H,
m), 6.35 (1H, d, J ¼ 2.9 Hz), 5.96 (1H, d, J ¼ 2.3 Hz), 5.58 (1H, t,
J ¼ 10.0 Hz), 5.48e5.43 (1H, m), 4.55 (1H, d, J ¼ 10.0 Hz), 4.29
(1H, dd, J ¼ 9.4 and 7.1 Hz), 3.31 (1H, d, J ¼ 12.7 Hz), 3.28e3.18
(1H, m), 2.80 (1H, dd, J ¼ 13.5 and 4.9 Hz), 2.72 (1H, dd,
J ¼ 12.9 and 10.7 Hz), 2.54 (1H, d, J ¼ 13.5 Hz), 1.91 (3H, br s).
HRMS-FAB: m/z (Mþ þ Na) calcd for C23H22O7 433.1263, found
433.1250.2.8. 2-(Naphthalen-1-yl)acetate 51 (DETD-35) (Method
A)
1H-NMR (400 MHz, CDCl3): 7.91e7.84 (2H, m), 7.81 (1H, d,
J ¼ 8.0 Hz), 7.51 (1H, d, J ¼ 9.6 Hz), 7.53e7.50 (1H, m), 7.44 (1H,
t, J ¼ 8.0 Hz), 7.37 (1H, d, J ¼ 6.4 Hz), 6.85 (1H, s), 5.88 (1H, d,
J ¼ 3.1 Hz), 5.44e5.38 (1H, m), 5.20 (1H, t, J ¼ 10.0 Hz), 5.06
(1H, d, J ¼ 2.7 Hz), 4.33 (1H, d, J ¼ 10.0 Hz), 4.13e4.00 (1H, m),
4.07 (2H, d, J ¼ 10.8 Hz), 3.18 (1H, br d, J ¼ 12.9 Hz), 2.93e2.86
(1H, m), 2.77 (1H, dd, J ¼ 13.4 and 4.8 Hz), 2.55 (1H, dd,
J ¼ 12.9 and 10.8 Hz), 2.50 (1H, d, J ¼ 13.4 Hz), 1.81 (3H, d,
J ¼ 1.0 Hz). HRMS-FAB: m/z (Mþ þ Na) calcd for C27H24O6
467.1471, found 467.1475.2.9. 2-(Naphthalen-1-yl)acetate 63 (epi-51)
Diethyl azodicarboxylate (0.05 mL, 0.32 mmol) was added to a
solution of 2 (51mg, 0.20mmol), 1-naphthylacetic acid (42mg,
0.23 mmol) and triphenylphosphine (68 mg, 0.26 mmol) in
tetrahydrofuran (1.5 mL). The mixture was stirred for 2 h at
room temperature. After removal of volatile solvent, the resi-
due was purified by flash column chromatography (SiO2,
AcOEt/Hexane gradient) to provide 63 (41 mg, 78%). 1H-NMR
(400 MHz, CDCl3): 7.96e7.91 (1H, m), 7.91e7.85 (1H, m), 7.80
(1H, d, J ¼ 8.3 Hz), 7.57e7.47 (2H, m), 7.43 (1H, dd, J ¼ 8.3 and
6.9 Hz), 7.37 (1H, d, J ¼ 6.9 Hz), 7.03 (1H, br s), 6.20 (1H, d,
J ¼ 3.4 Hz), 5.84 (1H, d, J ¼ 16.0 Hz), 5.45 (1H, d, J ¼ 3.4 Hz),
5.27 (1H, dd, J ¼ 16.0 and 9.6 Hz), 5.24e5.17 (1H, m), 4.44e4.35
(1H, m), 3.99 (2H, s), 3.57e3.48 (1H, m), 3.21 (1H, br d,
J ¼ 13.0 Hz), 2.83 (1H, t, J ¼ 12.2 Hz), 2.56 (1H, dd, J ¼ 14.6 and
6.4 Hz), 2.32 (1H, d, J ¼ 14.6 Hz), 2.51 (1H, d, J ¼ 13.0 Hz), 1.71
(1H, s). HRMS-FAB: m/z (Mþ þ Na) calcd for C27H24O6
467.1471, found 467.1473.
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The human normal epithelial cell line M10 and breast cancer
cell lines mouse TS/A (ERþ), human MDA-MB-231 (ER,
HER2, PR), and human MCF-7 (ERþ, HER2), brain cancer
cell line U-87MG, colon cancer cell line HCT-116, kidney can-
cer cell line A498, lung cancer cell line PC6, lymphoma line
U937, neuroepithelioma line SK-N-MC, stomach cancer cell
line KATO III and uterus cancer cell line NES-SA obtained
from the ATCC (Manassas, VA) were grown in the manufac-
turers’ suggested medium supplemented with 10% heat-
inactivated fetal bovine serum, 100 units/mL penicillin, and
100 mg/mL streptomycin, at 37 C in a humidified 5% CO2
incubator.
2.11. Cell viability assay
Normal or cancer cells (2 103e1 104 cells/well) were seeded
in a 96-well plate overnight and treated with different com-
pounds for 24 he72 h. Cells growth were determined by
MTT-based colorimetric assays as previously described (Lee
et al., 2010). Viability of the test cells treated with vehicle
(0.5% DMSO) only was defined as 100% viable. Survival of cells
after treatment with DETDs was calculated using the
following formula: viable cell number (%) ¼ OD570 (treated
cell culture)/OD570 (vehicle control)  100.
2.12. Cell cycle analysis
To determine the effects of DET, DETD-35 and PTX on the cell
cycles distribution, 5 104 MDA-MB-231 cells were plated in 6-
well cell culture plates and filled with DMEM culture medium
containing 0.5% fetal bovine serum (FBS). After 24 h, the low-
serum (0.5% FBS) medium was replaced by medium contain-
ing 10% FBS, and the MDA-MB-231 cells were treated with
their respective half maximal inhibitory concentration (IC50)
values of DET, DETD-35 and PTX for 48 h. After treatment,
both adherent and floating cells were collected, washed with
PBS and fixed with 1 mL of ice-cold 70% ethanol overnight at
4 C. Cells were stained with 1 mL of PBS containing 20 mg/
mL RNase, 1 mL triton X-100 and 20 mg/mL propidium iodide
and incubated in the dark for 30 min at room temperature.
The distribution of cells in the cell-cycle phases were analyzed
from the DNA histogram using a FACS Caliber flow cytometry
(Coulter Epics XL; Beckman Coulter, Miami, FL).
2.13. Boyden chamber assay
To test the anti-migratory and anti-invasive effect of DET,
DETD-35 and PTX, Boyden chamber assay was carried out.
MDA-MB-231 cells were placed into the upper chamber
(5  104 cells per insert) with DMEM culture medium contain-
ing 0.1% FBS. Ten percent FBS was added to the lower well of
the chamber (6.5 mm diameter, 8 mm pore size; Costar, Cam-
bridge, MA) as a chemoattractant and then it was filled with
DMEM culture medium containing vehicle (DMSO, 0.5%),
DET (2.5 and 4 mM), DETD-35 (1.25 and 2.5 mM), or PTX (2.5
and 4 mM). After 24 h incubation at 37 C in a 5% CO2 atmo-
sphere, non-migrating cells were scraped from the upper sur-
face of the membrane using a cotton swab, and the migratedcells remaining in the well were fixed and stained with DAPI
solution (4,6-diamidino-2-phenylindole, 1 mg/mL). The
migrated cells were counted in three fields at 20 original
magnifications by inverted fluorescence microscopy. To test
the anti-invasive effect of the compounds, 8 mm filters were
pre-coated with Matrigel (30 mg per filter) and incubated at
37 C for 2 h, then the protocol of migration assay described
above was followed.
2.14. Compound-drug combination assay
The synergistic effects between the DETDs and PTX were
determined with a range of concentrations of DETDs and
PTX as indicated. Briefly, cells (1.5  103e5  103 cells/well)
were seeded in 96-well plates and treated with compounds
or drugs alone or in combination for 24 he72 h. Cell prolifera-
tion was measured by MTT assay. Isobologram analysis and
Chou-Talalay method were used to determine the effects of
compound-drug combinations. The interaction between
DETDs and PTX was determined by the combination index
(CI), and the CI plot was generated using CalcuSyn software.
The combined effects of two compounds can be categorized
as follows: CI ¼ 1 indicates additive interaction, CI <1 indi-
cates synergism, and CI>1 indicates antagonism (Chou, 2010).
2.15. Time-lapse microscope analysis
A 12-well cell culture plate was coated with 25 mg/mL fibro-
nectin for 1 h and then seeded with 5  104 MDA-MB-231 cells
in DMEM containing 10% serum. Twelve hours after seeding,
time-lapse microscopy experiments were performed on an
inverted confocal microscope (LSM 510 META) equipped with
an environmental chamber with phase-contrast optics (im-
ages taken every 30 min). Using the object-tracking applica-
tion of Metamorph software (Molecular Devices), an average
of 12 subsequent cell centroid displacements/30 min between
two consecutive images were evaluated as cell velocities of
migration. In total, cell trajectories were recorded for 24 h.
These assays were made in treatments with vehicle (DMSO,
0.5%), DET (2.5, 4 and 10 mM), and DETD-35 (1.25, 2.5, 4 mM)
added at the beginning of the time-lapse imaging.
2.16. Lung metastatic animal model of TNBC
Seventy female SCID mice (5 weeks old) were randomly
assigned to 7 groups: PTX-5 group (5 mg/kg paclitaxel),
DETD-35-2 group (2 mg/kg DETD-35), DETD-35-10 group
(10 mg/kg DETD-35), PTX-5 þ DETD-35-2 group (5 mg/kg pacli-
taxel and 2 mg/kg DETD-35 alternate administration of eleven
doses of PTX and ten doses of DETD-35 in total), tumor control
group (5% DMSO), and sham control group (5% DMSO). In the
Pre-DETD-35-10 group, the mice were administered 10 mg/kg
DETD-35 every two days for three doses before i.v. injection
of 1  106 MDA-MB-231 tumor cells at day 0. All drug or com-
pounds dissolved in 5% DMSO were injected i.p. every three
days starting from day 1. Based on preliminary tests results,
we sacrificed the test mice by cervical dislocation at day 71
and dissected and necropsied the tumors metastasized to
the lung tissues. Other organs, including liver, kidney and
spleen were also collected for histological examination. The
Figure 1 e Hydrolysis of DET to form 2.
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Body weight was recorded and organ index (% organ weight/
body weight) was calculated.
2.17. Histology and immunohistochemistry
The lung organs of test mice were removed, fixed in 10% buff-
ered formalin and then embedded in paraffin. Paraffin-
embedded organs were sectioned (4 mm) for hematoxylin
and eosin (H&E) staining. Lung tissues were subjected to
immunohistochemical staining with rabbit antibodies against
vascular endothelial growth factor (VEGF), Ki-67, cyclooxyge-
nase-2 (COX-2), and caspase 3, respectively. The expression
levels of specific immunostaining detected proteins were
calculated according to the manufacturer’s protocol (Nichirei
Bioscience) by AxioVision software (Carl Zeiss MicroImaging,
Thornwood, NY).
2.18. Western blot analysis
Total cellular proteins were prepared from test cells as previ-
ously described (Ho et al., 2012). Protein concentration was
determined by the Bradford method (Bio-Rad). Protein sam-
ples were resolved by 4%e20% gradient SDS-PAGE and then
underwent immunoblotting. Primary antibodies against PN-
1, Slug, vimentin, and VEGF were from Santa Cruz Biotech-
nology (Santa Cruz, CA); E-cad, Snail, PARP, ZO-1, and ZEB-1
were from Cell Signaling Technology (Danvers, MA); and actinFigure 2 e Structure confirmatwas from Merk Millipore. Appropriate horseradish
peroxidase-conjugated secondary antibodies were used. Pro-
tein bands reacting to specific antibody were visualized by
use of enhanced chemiluminescence (Amersham) with expo-
sure to chemiluminescence light film (BioMax; Kodak).3. Results and discussion
3.1. Synthesis of DET derivatives
The parental compound DETwas isolated and purified from E.
scaber according to the method published elsewhere (Huang
et al., 2010), with a purity of more than 96% as judged by
HPLC and NMR spectrometry analyses data. The hydrolysis
of DET (1) with 1 N NaOH followed by acidic treatment pro-
duced novel sesquiterpene dilactone alcohol 2 through C-
7eC-8 lactonization of carboxylic acid 5, which was generated
by the cleavage of an ester and two lactone rings (Figure 1).
This translactonization process is similar to the case of ele-
phantopin, which is D4,5-epoxylated DET, to produce elephan-
tol (Kupchan et al., 1969). In the case of cnicin, a sesquiterpene
mono-lactone, C-8 alcohol was successfully obtained without
lactone ring transformation under mild basic conditions with
Na2CO3 (Bruno et al., 2003). Thus, we expected that three alco-
hols 2e4 might be produced through re-lactonization by the
control of basic conditions; however, the alcohols 3 and 4
were not derived under any kind of hydrolysis conditions,ion of 2 by X-ray analysis.
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zation analysis (Chembridge software, Chem3D Pro Ver.
13.0.2.3021), alcohol 2 clearly showed low energy of
40.37 kcal/mol, while C-8 alcohol 3 (235.17 kcal/mol) and C-2
alcohol 4 (61.76 kcal/mol) indicate higher energy (Supporting
information). This result suggests that the C-7eC-8 lactone
ring on 2 is easier to form than the C-6eC-7 lactone on 3
and the C-8eC-10 lactone on 4. In addition, it became clear
that the a-methylene-g-lactone ring in DET is extremely
strained. The structure of C-6 alcohol 2 was confirmed by X-
ray crystallography (Figure 2).
With alcohol 2, various acyl groups were introduced to
obtain the esters 6e63 (Figure 3, Table 1). An ester group often
plays a crucial role not only in drug efficacy, but also as an
important factor in biological activity. For instance, a lipo-
philic conjugated ester group at C-6 in helenalin, a sesquiter-
pene lactone, clearly contributed to its cytotoxicity against
cancer cells in vitro and in vivo (Beekman et al., 1977; Lee
et al., 1973). Designated ester groups were roughly classified
into two groups, aliphatic group 6e27 and aromatic group
28e63. An aliphatic group might influence hydrophobicity,
and its structure as well as size might affect interactions
with the feature of the binding pocket of target protein/
enzyme. On the other hand, an aromatic group may
contribute to planarity/hydrophobicity as well as the pep, p-
anion/cation, and/or p-OH interactions with the target pro-
tein/enzyme. Some of the ester groups were selected to be
incorporated into 2 based on the structural features of other
bioactive terpenoids; for example, methacrylate (DET side
chain) for 7, (E )-3,4-dimethylpent-2-enoate (bruceantin side
chain) for 16, 2-acetoxy-2-methylbutanoate (glaucarubinone
side chain) for 23, and cinnamate (from the SAR study of hel-
enalin analogue) for 28 (Lee et al., 1973). Esterifications of 2
were achieved by the following standard methods as shown
in Figure 3: (a) Treatment of 2 with the related carboxylic
acid (RCOOH), 1-(3-dimethylaminopropyl)-3-ethylcarbodi
imide hydrochloride (EDCI) and dimethylaminopyridine
(DMAP) to obtain the related esters 7e24, 28e43 and 47e62;
(b) Treatment of 2 with the related acid chloride (RCOCl) and
triethylamine to obtain the esters 25e27 and 44e46; (c) Treat-
ment of 2with 1-naphthylacetic acid under Mitsunobu condi-
tions (Mitsunobu, 1981) to provide 63 accompanied with
stereoinversion of C-6 (epi-51). Acetate 6 was produced as a
side product during the preparation of 24 by removal of 2,4-
dimethylpentan-3-one. The structures of all synthesized
DETD were confirmed by 1H-NMR and high resolution MS
spectra.Figure 3 e Preparations of ester analogues 6e63. Reagents and conditions
CH2Cl2, rt; (C) 2-(naphthalen-1-yl)acetic acid, PPh3, DEAD, THF, rt.3.2. Anti-proliferative effects against breast cancer cell
lines and SAR analysis
All the newDETDs 2e63 together with the parent DET (1) were
evaluated for their anti-proliferative activities against murine
mammary cancer cell line TS/A (ERþ, HER2) and human
breast cancer cell lines MDA-MB-231 (ER, PR, HER2),
MCF-7 (ERþ, HER2), and normal mammary M10 as shown
in Table 2. The IC50 values were analyzed by MTT assay in a
24-h treatment against the respective cells. The IC50 of DET
for TS/A and MCF-7 cells was determined at 2.3 mM, and
much less effect was observed for MDA-MB-231 cells with
IC50 of 14.0 mM. The cytotoxicity of C-6 alcohol 2 without an
ester group is diminished in comparison with the parent
DET (1). However, most of the ester analogues of 2 display
potent anti-proliferative activities against the tested breast
cancer cell lines with less toxicity against normal mammary
cells M10. Interestingly, methacrylate 7 keeping the same
ester group as DET but at a different position obviously
enhanced the anti-proliferative activity against human
TNBC cell line MDA-MB-231, suggesting that the C-7eC-8
lactone ring contributes more anti-proliferation activity
against MDA-MB231 than the C-6eC-7 lactone ring. The SAR
of synthesized DETDs is summarized in Figure 4. Among all
the aliphatic esters, the a,b-unsaturated ketone and/ormethyl
substituent at a-position have a tendency to increase the anti-
proliferative activity (Figure 4A). Carbon chain length also
affected the activity as indicated by the reduced activity of
C1 linear 6 and C7 linear 21. Of the cyclic aliphatic esters
25e27, cyclohexane 27 was more active against MDA-MB-
231 and MCF-7 cells than 25 and 26 (Figure 4B). Ester substitu-
ents carrying an aromatic function also displayed potent cyto-
toxicity. In the case of cinnamate derivatives (Figure 4C)
28e41, 3-methoxycinnamate 33 (designated DETD-39)
exhibited strong inhibitory effects against all tested breast
cancer cells, which was the most potent among all synthetic
analogues; however, it also showed toxicity against normal
cell line M10. Decreased cytotoxicities were found in fluorine
substituted and 3,4-dimethoxylated analogues 34e36. Ana-
logues 42e48 with benzoate-like groups also effectively
inhibited the growth of breast cancer cells. Of note, 4-
bromobenzoate 46 demonstrated the most potent anti-
proliferate activity against MDA-MB-231 (Figure 4D). Of the
naphthalene acetate group 51e61 and 63, the simple naph-
thalene acetate 51 (designated DETD-35) displayed great
anti-proliferative activity against all breast cancer cell lines,
and of particular note, showed no inhibitory effect on M10: (A) RCOOH, EDCI, DMAP, CH2Cl2, rt; (B) RCOCl, Et3N,
Table 1 e Functional R group structures of DET analogues 2-62. Stereochemistries of all chiral centers are racemate, unless indicated.
R R R R
2 H 20 35 Ri0 ¼ 3-CF3 50
6 21 36 R0 ¼ 3,4-diOMe 51 DETD-35
7 22 37 R0 ¼ 3-OEt 52
8 23 9 38 R’ ¼ 4-OEt 53
9 24 39 54
10 25 40 55
11 26 41 56
12 27 3 42 57
13 28 DETD-6 4 43 58
14 29 R0 ¼ 3,4,5-tri-OMe 44 DETD-32 R0 ¼ 4-OMe 59
15 30 R0 ¼ 4-OMe 45 R0 ¼ 4-Me 60
16 31 R0 ¼ 4-Me 46 R0 ¼ 4-Br 61
17 32 R0 ¼ 4-Cl 47 62
18 33 DETD-39 R0 ¼ 3-OMe 48
19 34 R0 ¼ 3-OCF3 49
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such as 56 and 59 can effectively inhibit the cell growth of
MDA-MB-231, while less inhibition was observed against
MCF-7.
Because most analogues showed similar cytotoxicity in
Table 1, we therefore selected four compounds from aromatic
esters 28e63 to see the effect of the distance between the ar-
omatic ring and the terpene skeleton, the effect of the func-
tional group on the aromatic ring, and the effect of p
electron system. With that, 28 and 33 with the electron-
withdrawing group were selected from the cinnamate group,
28e41, which has two carbons between the aromatic ring
and the ketone. 44 was selected from 42e48, which where
the aromatic ring is attached directly to the ketone. 51 was
selected from 49e61, which where one carbon exists between
the aromatic ring and the ketone. Furthermore, 51 possesses a
10 p electron system rather than 6p. The Table 3 data show
the toxicity results against different cancer cell lines by ana-
logues 28 (DETD-6), 33 (DETD-39), 44 (DETD-32), and 51
(DETD-35). In addition to effectively inhibiting breast cancer
cell proliferation, the four tested analogues also showed supe-
rior inhibition against brain, lung, lymphoma, neuroepithe-
lioma, kidney, prostate, stomach, colon and uterus cancerTable 2 e Cytotoxicity of synthesized DET analogues.
50% Inhibitory concentration (mM)a,b
TS/A MDA-MB-231 MCF-7 M10
1 2.3 14.0 2.3 e
2 7.5 e e e
6 3.5 e 6.7 e
7 1.8 6.2 2.4 e
8 1.9 7.5 3.7 e
9 1.7 4.6 3.5 e
10 2.1 7.0 3.9 e
11 2.7 5.9 3.4 e
12 1.9 6.7 3.4 e
13 2.3 e 3.9 e
14 4.0 e 5.8 e
15 1.6 4.6 2.4 e
16 3.3 7.0 4.2 e
17 3.3 5.5 2.6 e
18 2.2 5.8 3.5 e
19 4.0 e 4.5 e
20 1.8 4.3 2.5 4.7
21 e e e e
22 e e e e
23 2.9 e 4.2 e
24 2.4 5.9 2.5 e
25 2.4 8.7 7.1 e
26 3.0 6.7 6.2 e
27 2.6 5.2 4.6 e
28c 1.6 4.2 1.6 4.9
29 1.8 6.1 2.3 e
30 1.5 4.1 3.7 4.7
31 2.4 3.6 3.7 e
32 1.8 4.2 3.6 4.8
33c 0.8 1.9 2.1 3.7
a Breast cancer cell lines; TS/A (ERþ, HER2), MDA-MB-231 (ER, PR, H
b IC50 was not detectable at 0e5 mM for TS/A, MCF-7, and M10; 0e7.5 mM
c 28 (DETD-6), 33 (DETD-39), 44 (DETD-32), 51 (DETD-35).cell proliferation. The most marked suppression effect among
the different cancer types was observed in 51 (DETD-35) with
no detected toxicity against M10 (Tables 2 and 3). 28 (DETD-6)
and 33 (DETD-39) showed novel activity against different can-
cer types, but they were also toxic to normal cells in vitro.
Thus, 51 (DETD-35) was chosen to be further examined for
its effects on TNBC cell activity and the underlying mecha-
nisms, along with the parental compound DET. The anti-
cancer drug PTX was studied in parallel as a control and refer-
ence drug.3.3. DET, DETD-35 and PTX induce cell-cycle arrest or
apoptosis
We determined the regulatory effects of DET, DETD-35 and
PTX on the cell-cycle of MDA-MB-231 cells. Flow cytometric
results revealed that when cells were treated for 48 h with
vehicle (DMSO) or at the respective concentrations (IC50
values) of DET (14 mM), DETD-35 (3.8 mM) and PTX (60 mM)
(Figure 5A) the G0/G1 phase DNA contents were decreased
from 51.5% (vehicle control) to 36.2%, 39.0%, 11.2%, respec-
tively, whereas the apoptotic sub-G1 DNA content was
increased from 1.3% to 19.3%, 21.4%, and 66.8%, respectively50% Inhibitory concentration (mM)
TS/A MDA-MB-231 MCF-7 M10
34 e >15 e e
35 e 8.2 e e
36 e 9.5 e e
37 4.4 7.7 e e
38 2.1 2.7 3.3 4.0
39 2.5 3.4 3.6 4.7
40 2.2 4.9 4.1 e
41 2.7 6.0 4.5 e
42 2.4 4.3 3.7 e
43 2.0 4.5 5.9 e
44c 1.9 3.9 4.3 e
45 1.8 4.2 2.7 e
46 3.0 2.2 6.1 e
47 3.1 4.9 6.1 e
48 2.8 5.0 5.3 e
49 2.4 6.9 e e
50 2.2 7.0 e e
51c 1.7 3.5 3.2
52 2.0 3.1 3.1 4.7
53 e >15 e e
54 3.8 7.3 e e
55 4.1 3.8 4.1 4.8
56 3.1 4.9 e e
57 1.9 4.2 4.5 e
58 e >15 e e
59 2.8 4.1 e e
60 2.1 3.8 3.8 5.8
61 3.5 5.1 e e
62 e >15 e e
63 e 7.4 e e
ER2), MCF-7 (ERþ, HER2), M10 (normal mammary).
for MDA-MB-231.
Figure 4 e Summary of structure-activity relationship of DET analogues in inhibition of proliferation of TS/A, MCF-7, MDA-MB-231 breast
cancer cells or M10 normal mammary cells. (A) Aliphatic ester derivatives (6e24); (B) Cyclic aliphatic esters (25e27); (C) Cinnamate derivatives
(28e41); (D) DETDs carrying benzoate-like structures (42e48); (E and F) Naphthalene acetate derivatives (49e62). Among all, naphthalene
acetate 51 (DETD-35) showed significantly potent cytotoxicities against all types of tested breast cancer cell lines without growth inhibition of
normal mammary M10 cells. Cinnamate 33 (DETD-39) strongly inhibited the growth of all tested breast cancer cells; however, it also inhibited
normal mammary cell growth.
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231 cells treated with PTX was observed. In comparison, DET
or DETD-35-treated cells did not show any cell-cycle arrest
at specific stages, but cell apoptosis was significantly inducedTable 3e Summary of the 50% inhibitory concentration (IC50, mM) of DE
types. The cells were treated with compound for 24 h and then subjected
Cell name Tumor origin 1 DET 28 (DETD
MCF-7 Breast 5.0 4.8
MDA-MB-231 Breast 14.0 4.0
TS/A (mouse) Breast 2.6 1.8
B16eF10 (mouse) Skin 6.00 3.90
U-87MG Brain 1.00 0.35
PC6 Lung 0.40 0.17
U937 Lymphoma 0.48 0.18
SK-N-MC Neuroepithelioma 0.51 0.32
A498 Kidney 2.82 1.11
PC3 Prostate 12.8 4.5
KATO III Stomach 1.47 0.42
HCT-116 Colon 0.28 0.11
NES-SA Uterus 0.90 0.42at 48 h treatment. Expression of full-length and cleaved poly
ADP-ribose polymerase (PARP), a protein marker for pro-
grammed cell death which upon cleavage will lead to
apoptosis, was evaluated by western blotting as shown inT and the selected DETDs on inhibiting viability of various cancer cell
to MTT assays.
-6) 33 (DETD-39) 44 (DETD-32) 51 (DETD-35)
2.4 4.3 3.9
1.9 3.9 3.5
0.8 1.9 1.7
1.70 4.20 2.70
0.15 0.42 0.34
0.11 0.47 0.34
0.10 0.39 0.18
0.11 0.51 0.26
0.48 1.48 0.79
2.6 6.2 5.5
0.29 0.82 0.65
0.10 0.36 0.14
0.14 0.50 0.34
Figure 5 e (A) The effect of DET, DETD-35 and paclitaxel on inhibiting MBA-MB-231 cell viability determined by MTT assay. (B) Flow
cytometry analysis of DNA distribution (%) in MDA-MB-231 cells treated with vehicle, DET, DETD-35, or PTX at indicated times. Cells were
stained with 20 mg/mL propidium iodide in the dark before analysis. The percentage of DNA at sub-G1, G0/G1, S and G2/M phases were
calculated. Presented data are representative of three independent experiments. (C) Western blot analysis of apoptotic marker PARP. Expression
levels of full-length PARP (upper row) and cleaved PARP (lower row) were quantified and normalized with loading control actin.
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age in PARP, while 48-h PTX treatment reduced the expression
of full-length PARP. These results indicate that different
mechanisms may underlie the three treatments although
they all show effects on inducing the apoptotic sub-G1 content
in cell cycle analysis.3.4. Inhibitory effects on MDA-MB-231 cell migration,
invasion, and motility
Boyden chamber assay was used to investigate the effects of
DET and DETD-35 on the migration and invasion activity of
MDA-MB-231 cells, and PTX was used as a reference control.
Figure 6A shows that DET (2.5 and 4 mM), DETD-35 (1.25 and2.5 mM) and PTX (2.5 and 4 mM) significantly inhibited cell
migration in a concentration-dependent manner under 24-h
treatment. The high concentrations of DET, DETD-35 and
PTX greatly reduced by 77%, 84% and 88%, respectively, cell
migration, as compared to the vehicle control group, while
the suppressed effect of the low concentration of DET,
DETD-35 and PTX was 16%, 10% and 87%, respectively
(P < 0.05). Transwell invasion assay further revealed that
DET and DETD-35 inhibited invasion of MDA-MB-231 cells
through a thin Matrigel matrix. It was observed that the high
concentration of DET, DETD-35 and PTX significantly inhibited
cell invasion by 76%, 80% and 90%, respectively, and the anti-
invasion effect of the low concentrations were 57%, 65% and
85%, respectively (P< 0.05, Figure 6B). These data demonstrate
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invasion activity against MDA-MB-231 cells, with DETD-35
exerting a better activity than DET.
The kinetic characteristics of MDA-MB-231 cell motility
treatedwithDET or DETD-35 for 24 hwere further investigated
by time-lapse confocal microscope. Trajectories of migrating
MDA-MB-231 cells under different treatment conditions
were monitored and analyzed over a 24-h period. Vehicle
control-treated cells were observed to bemoving energetically
with robust membrane protrusion resulting in a continuous
motion (0e24 h) (Figure 7A). As shown in Figure 7B, the most
significant cell dispersion area from the origin was observed
in vehicle control, and a relatively small area due to restricted
movements was seen in cells treated with 2.5 mMDET for 12 h.
Considerably reduced cell trajectories were observed in cells
treated with 4 and 10 mM DET, or 1.25, 2.5 and 4 mM DETD-35,
respectively. The migration velocities of MDA-MB-231 cells
under each treatment were further monitored and measured
every 30 min. In cells treated with DETD-35 at 1.25, 2.5 and
4 mM, and the higher concentrations of DET at 4 and 10 mM,
the suppression of movement became much more prominent
with the average motility velocity decreasing significantly
compared to vehicle control cells and cells treated with
2.5 mM DET (Figure 7C). Furthermore, the migrated distances
were significantly shorter in 2.5, 4, 10 mM DET and 1.25, 2.5,
4 mM DETD-35 treated cells (144 vs. 15 vs. 9 and 70 vs. 23 vs.Figure 6 e Representative photomicrographs of (A) migration analysis and (B
DETD-35 and PTX, respectively for 24 h by Boyden chamber assay. Nuclei
experiments. Different letters indicate significant differences (P< 0.05, o3 mm) than that of the control (186 mm) (Figure 7D). These re-
sults indicate that DETD-35, a newly synthesized sesquiter-
pene lactone exhibits potent and better bioactivity than DET
in suppressing MDA-MB-231 cell motility.
Expression profiles of several epithelial-to-mesenchymal
transition protein markers in MDA-MB-231 cells were also
evaluated as shown in Figure 8. Cancer cells with metastatic
characteristics are known to lose adherence-related proteins,
or epithelial-like proteins. DET and DETD-35 both showed a
better effect on retaining E-cadherin (E-cad) expression in
comparison to PTX, while DETD-35 showed the most signifi-
cant activity in retaining the tight junction protein zonula
occludens-1 (ZO-1) among the three treatments. DET and
DETD-35 did not regulate the expression of vimentin, an inter-
mediate filament protein expressed mostly in mesenchymal
cells, which on the other handwas time-dependently downre-
gulated by PTX. Transcription factors resulting in the repres-
sion of E-cad including Snail, Slug, and ZEB-1 were
expressed differently among the three treatments. DET treat-
ment reduced ZEB-1 expression level to 49% at 48 h while
DETD-35 exerted the same effect at an earlier stage at 24 h. Ex-
pressions of VEGF and protease nexin-1 (PN-1), a serine prote-
ase inhibitor, were downregulated in DET- and PTX-treatment
but not in DETD-35 treatment. These protein expression data
not only demonstrated the mechanistic insights of the com-
pound modulation in breast cancer cell migration, invasion,) invasion analysis of MDA-MB-231 cells treated with vehicle, DET,
were stained with DAPI. Data are mean ± SEM of three independent
ne-way ANOVA).
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exerted on MDA-MB-231 cells among DET, DETD-35, and PTX.
3.5. Synergism between DETD-35 and PTX against
MDA-MB-231 cells
Combining cytotoxic drugs, such as PTX, with less toxic bio-
logical agents is one way to relieve side effects, especially in
adjuvant therapy (Oakman et al., 2009). The identification
and validation of the potential benefits of phytocompounds
with low toxicity but effective for cancer inhibition has thus
become an important area of pharmaceutical science
(Newman and Cragg, 2007). The pressing need for develop-
ment of new therapeutic or preventive agents for cancerFigure 7 e Migration kinetics of MDA-MB-231 cells treated with DET an
vehicle, DET or DETD-35. (B) Time-lapse sequence of image frames. In
displayed in diagrams. (C) Average migration velocities of cells undergoing
period. (D) Total migrated distances of cells undergoing each treatment afte
letters represent significant differences (P< 0.05, one-way ANOVA).diseases has spurred the search for bioactive phytocom-
pounds or their derived analogues with novel modes of action
or improved efficacy (Lin et al., 2012; Newmanand Cragg, 2007;
Pan et al., 2010). To investigate whether DETD-35 acts syner-
gistically with PTX against MDA-MB-231 cell activity, anti-
proliferation assay using MTT reagent was first performed to
obtain IC values of each compound. IC40 of PTX and DETD-35
on MDA-MB-231 cells were shown as 23.8 nM and 3.32 mM,
respectively (Figure 9A). Further, cells treatedwith a fixed con-
centration of DETD-35 at 1 mMwere co-treated with ascending
concentrations of PTX (0e25 nM) and displayed better inhibi-
tory activity on cancer cell proliferation than PTX treatment
alone (Figure 9A and B). Based on the IC40 value of each com-
pound, we used concentrations of DETD-35 ranging fromd DETD-35. (A) MDA-MB-231 cell morphology after treating with
dividual trajectories of cells undergoing each treatment after 12 h are
each treatment shown at 30-min intervals throughout the observation
r 12 h. Data are mean ± SEM with n ‡ 12. Bars labeled with different
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bination study. Classic isobologram analysis and Chou-
Talalay method were conducted to investigate the synergistic
effect of compound and drug. Combination index (CI) was
calculated with the CalcuSyn software (Version 2.0, Biosoft)
and expressed as CI vs. Fa (fraction affected). CI <1 indicates
synergy; CI ¼ 1 indicates additive effect; and CI >1 indicates
antagonism. We observed that DETD-35 in combination with
PTX acts synergistically in inhibiting the growth of MDA-MB-
231 cells (Figure 9C and D).
3.6. DETD-35 potently suppressed lung metastasis of
MDA-MB-231 cells
To examine the drug efficacy in vivo, DETD-35 and the refer-
ence drug PTX were administrated before and/or after MDA-
MB-231 cell injection into xenograft mice. An alternate treat-
ment group was included in this study to evaluate the syner-
gistic effect of DETD-35 and PTX in animals in which mice
were administrated alternatively with a half of dose of either
compound in the single-treatment group. This treatment was
designed to seek a strategy to potentially reduce PTX-related
side effects but retain the same treatment efficacy.
DETD-35 pre-treatment at a dosage of 10mg/kg (pre-DETD-
35-10) was shown to significantly reduce the number of tumor
foci (83%) in the lungs of tumor-bearing mice especially when
treated before tumor occurrence, suggesting its potential
application as a preventive agent (Figure 10A). DETD-35 and
PTX post-treatment at 10 mg/kg and 5 mg/kg showed 50%
and 62%, respectively, reduction of lung tumor foci. DETD-35
at 2 mg/kg, however, showed little effect. Interestingly, the
alternate treatment group PTX-5 þ DETD-35-2 with adminis-
tration of DETD-35 at 2 mg/kg (10 doses) and PTX at 5 mg/kgFigure 8 e Western blot analysis of several epithelial-to-mesenchymal tran
drug or compounds. Protein expression levels were quantified and normali(11 doses) exerted a similar effect to that of PTX treatment
alone at 5 mg/kg (21 doses), implying a possible strategy to
reduce PTX cytotoxicity while retaining treatment efficacy at
the same time, as none of the treatments showed a negative
effect on the organ index of liver, kidney, spleen, and lung in
the tested animals (Figure 10B).
3.7. Histopathological and immunohistochemistry
analysis of lung tissues
Histopathology was performed using hematoxylin and eosin
(H&E) staining to depict the lung architecture within different
treatment groups. As shown in Figure 11, the sham control
mice showed typical lung alveoli architecture, and the tumor
control group showed fully grown tumormass,with the nuclei
becoming larger and more irregular compared with the sham
control group. DETD-35 inhibited histological alterations in
lung tissue in a dose dependent manner. The PTX groups
also expressed fewer alveolar defects compared to the tumor
control group. Compared to other treatment groups, pre-
treatment pre-DETD-35-10 and alternate-treatment PTX-
5 þ DETD-35-2 significantly inhibited tumor growth and
metastasis in mouse lung tissues.
The protein markers used in IHC staining correlate with
proliferation (Ki67), angiogenesis (VEGF), inflammation
(COX-2) and apoptosis (caspase 3) in lung mammary tumor
sites. Our results revealed that the protein expressions of
thesemarkers were significantly attenuated in DETD-35 treat-
ment compared with the corresponding tumor vehicle con-
trols in mice lung tissues (Figure 11). For lung samples taken
after 71 days of cancer cell injection into the tail vein, the over-
expression of Ki67 and VEGF were detected in the tumor con-
trol group which were suppressed in the DETD-35 and PTXsition protein markers in MDA-MB-231 cells treated with indicated
zed with loading control actin by densitometry.
Figure 9 e Compound-drug combination studies of DETD-35 and PTX against MDA-MB-231 cell proliferation. (A) Inhibition of cell
proliferation by PTX or DETD-35. Cells were treated with indicated concentrations for 24 h. Cell viability was determined by MTT assay. (B) Bar
graph showing the combination effect of PTX and DETD-35. (C) Classic isobologram analysis graph and (D) combination index (CI) plot of
DETD-35 co-treatment with PTX. CI< 1 indicates synergy; CI [ 1 indicates additive effect; and CI> 1indicates antagonism.
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and VEGF expression in lung tissue. Pre-treatment with
DETD-35 and alternate-treatment of DETD-35 with PTX signif-
icantly inhibited the protein expression levels of VEGF and
Ki67 aswell as on pro-inflammatory enzymeCOX-2 in lung tu-
mor foci, whereas increased expression of apoptotic marker
caspase 3 was found in the DETD-35, PTX and alternate-
treatment of DETD-35 with PTX groups (Figure 12). Together
with results from in vitro cell-based assays, analysis of protein
expression levels in metastatic MDA-MB-231 tumor xenograftFigure 10 e Effect of DETD-35 on the lung metastasis of MD-MB-231 trip
metastatic pulmonary foci in the lung organ in different treatment groups
analyzed (P< 0.05; one-way ANOVA).provides strong evidence to support the suppressive effect of
DETD-35 on TNBC metastasis.4. Conclusion
In summary, a novel sesquiterpene di-lactone 2was obtained
from a bioactive natural product, deoxyelephantopin (DET, 1)
by lactone ring transformation. Fifty-eight ester analogues of
2 were designed, synthesized and evaluated for anti-breastle negative mammary tumors in xenograft SCID mice. (A) Number of
was calculated. (B) Organ index in different treatment groups were
Figure 11 e Histological examinations of lung morphology and the effect of different drug treatments on the VEGF, Ki67 and COX-2 expression
in the lung tissues. Representative immunohistochemistry lung sections from each group stained for tumor blood vessel growth with VEGF, tumor
proliferating with Ki67, cellular inflammation with COX-2. Protein expression levels were compared with the sham control and tumor control
groups. Scale bar represents 100 mm.
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better anti-proliferative activity against TNBC cell line MDA-
MB-231 than that of parental DET. SAR study revealed the
a,b-unsaturated ketone and/or methyl substituent at the a po-
sition have a tendency to increase the anti-proliferative activ-
ity in the case of the aliphatic esters. Analogues with
cinnamates such as 33 (DETD-39), benzoates such as 44
(DETD-32), and naphthalene acetates such as 51 (DETD-35),
also showed potent anti-breast cancer activity. The most
potent analogue 51 (DETD-35) and the parentDETwere further
investigated for their anti-TNBC effects in vitro and in lung
metastasis xenograft mouse model using an MDA-MB-231
cell line. By employing various assays including cell viability
assay, Boyden chamber analysis, time-lapse microscopy, and
immunohistochemistry analysis, DETD-35 was shown to
exhibit a better effect thanDETon inhibiting cellmigration, in-
vasion, and motility of MDA-MB-231 cells in a concentration-
dependent manner. Among the designed compound and
drug administration strategies in the animal study, DETD-35pre-treatment (at 10mg/kg body weight) showed themost sig-
nificant reduction inmetastatic pulmonary foci (83%) of MDA-
MB-231 cells inmice; the alternate treatmentofDETD-35þPTX
also greatly reduced metastatic pulmonary foci (71%). Our
observation suggested that DETD-35 may have the potential
for further development into a complementary or sensitizing
agent to chemotherapeutic drugs especially for TNBC.Grant support
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